Literature DB >> 1931619

Involved field radiotherapy or chemotherapy in the management of stage I nodal intermediate grade non-Hodgkin's lymphoma.

G M Jeffery1, G M Mead, J M Whitehouse, R D Ryall.   

Abstract

Early stage intermediate grade non-Hodgkin's lymphoma (NHL) is frequently treated with chemotherapy alone or in conjunction with radiotherapy. We have managed clinical Stage I nodal, intermediate grade NHL with involved field radiotherapy alone for non-bulky (less than 5 cm post-surgery) disease or combination chemotherapy alone for more bulky disease. Forty-three patients were treated between 1978 and 1989. Of the 30 patients with non-bulky disease treated with radiotherapy, 29 (97%) achieved complete remission (CR). Thirteen (42%) patients relapsed after radiotherapy and ten of these achieved a further CR (durable in eight) following salvage chemotherapy. Eleven patients with bulky disease received combination chemotherapy with nine (82%) attaining CR (durable in eight). Two patients with bulky disease received radiotherapy-both achieved CR, but have relapsed and died of lymphoma. Overall actuarial 5 year survival for the total group is 77% with a median follow-up of 30 months (range 3-119 months). The 5 year actuarial survival for the 30 patients with non-bulky disease treated with radiotherapy is 86% at a median follow-up of 39 months (range 8-119 months). The 4 year actuarial survival of the 11 patients treated with chemotherapy is 60% with a median follow-up of 25 months (range 3-55 months). We conclude that involved field radiotherapy alone is efficacious for clinical stage I patients with non-bulky nodal intermediate grade NHL and that patients relapsing after radiotherapy are adequately salvaged by chemotherapy. Patients with bulky disease have an inferior survival and should receive combination chemotherapy.

Entities:  

Mesh:

Year:  1991        PMID: 1931619      PMCID: PMC1977466          DOI: 10.1038/bjc.1991.429

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  42 in total

Review 1.  The role of radiation therapy in the management of the non-Hodgkin's lymphomas.

Authors:  R T Hoppe
Journal:  Cancer       Date:  1985-05-01       Impact factor: 6.860

2.  Report of the Committee on Hodgkin's Disease Staging Classification.

Authors:  P P Carbone; H S Kaplan; K Musshoff; D W Smithers; M Tubiana
Journal:  Cancer Res       Date:  1971-11       Impact factor: 12.701

3.  The role of radiation therapy in the treatment of early stage large cell lymphoma.

Authors:  S H Levitt; C K Lee; C D Bloomfield; G Frizzera
Journal:  Hematol Oncol       Date:  1985 Jan-Mar       Impact factor: 5.271

4.  The roles of staging laparotomy, chemotherapy, and radiotherapy in the management of localized diffuse large cell lymphoma: a study of 75 patients.

Authors:  J N Lester; L M Fuller; F G Conrad; J A Sullivan; W S Velasquez; J J Butler; C C Shullenberger
Journal:  Cancer       Date:  1982-05-01       Impact factor: 6.860

5.  Chemotherapy as definitive treatment of stage I-II large cell and diffuse mixed lymphomas.

Authors:  F Cabanillas
Journal:  Hematol Oncol       Date:  1985 Jan-Mar       Impact factor: 5.271

6.  Mediastinal large-B-cell lymphoma with sclerosis: a clinical study of 21 patients.

Authors:  G Todeschini; A Ambrosetti; V Meneghini; G Pizzolo; F Menestrina; M Chilosi; F Benedetti; D Veneri; G L Cetto; G Perona
Journal:  J Clin Oncol       Date:  1990-05       Impact factor: 44.544

7.  Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I-II non-Hodgkin's lymphomas.

Authors:  P Mauch; R Leonard; A Skarin; D Rosenthal; S Come; J Chaffey; S Hellman; G Canellos
Journal:  J Clin Oncol       Date:  1985-10       Impact factor: 44.544

8.  Follicular large cell lymphoma: analysis and prognostic factors in 62 patients.

Authors:  H M Kantarjian; P McLaughlin; L M Fuller; D O Dixon; B M Osborne; F F Cabanillas
Journal:  J Clin Oncol       Date:  1984-07       Impact factor: 44.544

9.  Long-term survival of patients with localized diffuse histiocytic lymphoma.

Authors:  E E Vokes; J E Ultmann; H M Golomb; E R Gaynor; D J Ferguson; M L Griem; D Oleske
Journal:  J Clin Oncol       Date:  1985-10       Impact factor: 44.544

10.  Combined radiotherapy-chemotherapy for early stages non-Hodgkin's lymphoma: the 1975-1980 EORTC controlled lymphoma trial.

Authors:  P Carde; J M Burgers; M van Glabbeke; M Hayat; J M Cosset; R Somers; W Sizoo; M M Qasim; R Lefur; J S Abbatucci
Journal:  Radiother Oncol       Date:  1984-12       Impact factor: 6.280

View more
  2 in total

Review 1.  Combined chemotherapy plus radiotherapy for treatment of early-stage intermediate- and high-grade non-Hodgkin's lymphoma.

Authors:  J H Briggs; T P Miller
Journal:  Curr Oncol Rep       Date:  2000-03       Impact factor: 5.945

2.  Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy.

Authors:  B Vaughan Hudson; G Vaughan Hudson; K A MacLennan; L Anderson; D C Linch
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.